

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61K 9/127</b>		A2	(11) International Publication Number: <b>WO 97/35559</b>
			(43) International Publication Date: <b>2 October 1997 (02.10.97)</b>
(21) International Application Number: <b>PCT/US97/03380</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: <b>4 March 1997 (04.03.97)</b>			
(30) Priority Data: <b>60/014,227 27 March 1996 (27.03.96) US</b>			
(71) Applicant: ORTHO PHARMACEUTICAL CORPORATION [US/US]: US Route #202, Raritan, NJ 08869-0602 (US).		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(72) Inventors: KLIMCHAK, Robert, J.; 121 Rockafellow Mill Road, Flemington, NJ 08822 (US). GLAVINOS, Peter, G., Jr.; 890 Pebble Hill Road, Doylestown, PA 18901 (US).			
(74) Agents: CIAMPORCERO, Audley et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933-7003 (US).			

(54) Title: MANUFACTURE OF LIPOSOMES AND LIPID-PROTEIN COMPLEXES BY ETHANOLIC INJECTION AND THIN FILM EVAPORATION

(57) Abstract

A method for preparing liposomal suspensions which comprises preparing a solution of a poorly soluble protein or other poorly soluble compound and an encapsulating amount of a suitable lipid in an alcoholic solvent, injecting the resulting solution into an aqueous solution of appropriate ionic strength, and removing the alcoholic solvent by thin-film evaporation at the transition temperature of the liposomal suspension. This process is suitable for continuous production on an industrial manufacturing scale. It is of particular application in the preparation of KL4 pulmonary surfactant composition, wherein the thin film evaporation is conducted within the transition temperature range of the surfactant (approximately 35-50 °C), thereby enhancing the KL4 peptide insertion into the lipid bilayer and leading to a product with reduced viscosity and enhanced surface tension lowering properties.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**MANUFACTURE OF LIPOSOMES AND LIPID-PROTEIN COMPLEXES BY  
ETHANOLIC INJECTION AND THIN FILM EVAPORATION**

---

5

**Field of the Invention**

The present invention relates to the field of pharmaceutical compositions and the manufacture of liposomes and lipid-protein complexes by ethanolic injection. In another aspect, the invention relates to manufacture of synthetic lipid-protein pulmonary surfactant liposomal compositions suitable for the treatment of respiratory distress syndrome.

15

**Background of the Invention**

Liposomes are small vesicles comprising amphipathic lipids arranged in spherical bilayers. Liposomes may contain many concentric lipid bilayers separated by aqueous channels (multilamellar vesicles or MLVs), or alternatively, they may contain a single membrane bilayer (unilamellar vesicles), which may be small unilamellar vesicles (SUVs) or large unilamellar vesicles (LUVs). The lipid bilayer is composed of two lipid monolayers having a hydrophobic "tail" region and a hydrophilic "head" region. In the membrane bilayer, the hydrophobic "tails" of the lipid monolayers orient towards the center of the bilayer, whereas the hydrophilic "heads" orient toward the aqueous phase.

Liposomes may be used to encapsulate a variety of materials by trapping hydrophilic compounds in the aqueous interior or between bilayers, or by trapping

- 2 -

hydrophobic compounds within the bilayer. As such, they are particularly useful to deliver biologically active materials by encapsulating compounds which exhibit poor aqueous solubility or which exhibit unacceptable 5 toxicity at therapeutic dosages.

Liposomes and related phospholipid vesicle complexes can be prepared by a variety of techniques. In general, these techniques start with "dry" lipids 10 that are introduced into an aqueous phase (D. Lasic, J.Theor. Biol. (1987) 124:35-41). Once the lipid is hydrated, liposomes form spontaneously. Techniques have been developed to control the number of lamellae in the liposome and to produce defined particle size. U.S. 15 patent 4,935,171 discloses a single-vessel method of preparing liposomes by forming a homogeneous lipid-film in a thin-film evaporator by evaporation of the organic solvent, followed by *in-situ* hydration of the film in an aqueous phase by agitation.

20

Another method of preparing liposomes is known as the ethanolic injection process. (S. Batzre et al., Biochem. Biophys Acta (1973) 298:1015-1019; J. Kremer et al., Biochemistry (1977) 16:3932-3935). In this 25 process, the lipids are dissolved in ethanol and injected into the aqueous phase, optionally containing a buffer solution. This process generates unilamellar or multilamellar vesicles of defined size. One advantage of this process is that it permits continuous production 30 of vesicles if the solvent can be removed in a continuous process. Generally, the procedure requires removal of the solvent following injection of the solvent into the aqueous phase. This is generally accomplished by dialysis or other filtration processes

- 3 -

such as tangential flow filtration.

Pulmonary surfactant is a complex mixture of lipids and proteins that promotes the formation of a monolayer at the alveolar air-water interface and, by reducing the surface tension, prevents the collapse of the alveolus during expiration. Premature infants, and occasionally full term neonates, sometimes suffer from a condition known as respiratory distress syndrome (RDS) due to the lack of sufficient endogenous pulmonary surfactant. Artificial pulmonary surfactants have therefore been developed to treat this condition thereby reducing infant morbidity and mortality.

One of these artificial pulmonary surfactants, known as KL4, is disclosed in U.S. Patents 5,164,369 and 5,260,273, hereby incorporated by reference into the present application. Disclosed therein is a synthetic pulmonary surfactant composition comprising a pharmaceutically acceptable phospholipid admixed with a polypeptide having alternating hydrophobic and positively charged amino acid residues. As formulated for clinical use, the composition is a liposome comprised of dipalmitoyl-phosphatidylcholine (DPPC), palmitoyloleoylphosphatidylglycerol (POPG), palmitic acid (PA) and the synthetic peptide KL4 suspended in a buffered aqueous medium. The final drug product is a viscous suspension intended for direct instillation into the lung.

At present, this liposomal KL4 composition is formulated by the aforementioned ethanolic injection process. As described above, it is general practice to remove the ethanol solvent from the composition by

- 4 -

dialysis. However, the dialysis procedure is not satisfactory for the liposomal KL4 drug product due to the viscous nature of the product. There is thus a need for a method of removing the ethanol from liposomal 5 formulations prepared by ethanolic injection where the liposomal formulation is viscous as in the case of KL4. Advantageously, the solvent removal process should allow for continuous removal of the solvent during the manufacturing process.

10

In addition, it is noted that the extent of KL4 peptide insertion and the subsequent manner with which it associates with the components of the liposome lipid bilayer must be optimal for drug product performance 15 with respect to both surface tension lowering properties and viscosity (fluidity). One of the problems encountered in the formulation and performance of liposomal KL4 drug product is that the viscosity of the drug product can limit effective distribution in the 20 lung, thereby reducing *in vivo* activity. The present invention is intended to improve performance of KL4 liposomal pulmonary surfactant by facilitating protein insertion into the lipid bilayer and reducing viscosity of the final drug product.

25

#### SUMMARY OF THE INVENTION

A method for preparing liposomal suspensions which comprises preparing a solution of a poorly soluble 30 protein or other poorly soluble compound and an encapsulating amount of a suitable lipid in an alcoholic solvent, injecting the resulting solution into an aqueous solution of appropriate ionic strength, and removing the alcoholic solvent by thin-film evaporation

- 5 -

within the transition temperature range of the liposomal suspension. This process is suitable for continuous production on an industrial manufacturing scale.

5       In accordance with the present invention, protein insertion into the lipid bilayer of the liposome is optimized by conducting the solvent removal by thin-film evaporation within the transition temperature range of the protein. Protein insertion into lipid bilayers is  
10      optimal under those conditions in which the bilayer exists in a state of flux between "gel" and "liquid crystalline" phases - the transition temperature phase. The alcoholic solvent increases the fluidity of the lipid bilayer, thus allowing protein diffusion to the  
15      bulk phase (water) surrounding the bilayer. By conducting thin-film evaporation within the transition temperature range of the surfactant, protein in the bulk phase inserts into the lipid bilayer with less effort as the bilayer remains fluid within the transition  
20      temperature range. Otherwise, protein may remain in the bulk phase outside the bilayer resulting in greater drug product viscosity, and reduced activity.

25       In the case of KL4 pulmonary surfactant composition, the thin film evaporation is conducted within the transition temperature range of the surfactant (approximately 35-50°C), thereby enhancing the KL4 peptide insertion into the lipid bilayer and leading to a product with reduced viscosity and enhanced surface  
30      tension lowering properties.

- 6 -

#### DETAILED DESCRIPTION

The process of the present invention is carried out by dissolving the poorly soluble protein or other poorly soluble compound in an alcoholic solvent and adding an encapsulating amount of a suitable lipid(s). The resulting solution is then injected into an aqueous solution of appropriate ionic strength, forming the liposomes. The alcoholic solvent is then removed by thin-film evaporation conducted within the transition temperature range of the liposomal suspension.

The process is useful for the formulation into liposomes of poorly soluble proteins or other poorly soluble compounds for which liposomal delivery is desirable. Poorly soluble compounds are those which exhibit poor solubility (less than about 1mg/ml) at physiologic temperature and pH in aqueous solution. As mentioned, the process is particularly suitable for formulation of KL4 pulmonary surfactant, but is applicable to formulation of other liposomal drug products such as doxorubicin, amphotericin B and the like.

The alcoholic solvent is a lower alkanol of one to six carbon atoms, such as methanol, ethanol, n-propanol, isopropanol, n-butanol and the like. Solubilizing amounts of fluorinated alcohols such as 2,2,2-trifluoroethanol; 1,1,1,3,3-hexafluoro-2 propanol and the like may also be used as the solvent or may be added to the solvent mixture. The solvent may also optionally contain a solubilizing amount of an aprotic solvent such as dimethylsulfoxide (DMSO), dioxane, dimethylformamide (DMF) and the like.

- 7 -

The lipid is any of the known amphipathic lipid or phospholipid compositions generally used in the preparation of liposomes. Suitable lipids include dipalmitoyl-phosphatidylcholine (DPPC),  
5 palmitoyloleoylphosphatidylglycerol (POPG), palmitic acid (PA), egg phosphatidylcholine (EPC), egg phosphatidylglycerol (EPG), cholesterol, dimyristoylphosphatidylglycerol (DMPG), dimyristoylphosphatidylcholine (DMPC) and the like. The  
10 lipids are generally used in an amount sufficient to encapsulate the protein or poorly soluble compound and form liposomes of appropriate size. Selection of an appropriate encapsulating amount of the lipid will depend on the particular compound and process conditions  
15 selected and is within the skill of the art. (See G. Gregoriadis, "Liposome Technology" I-III CRC Press, Inc. Boca Raton Fla. 1984).

In accordance with known ethanolic injection procedures, the ethanolic/lipid suspension is injected into the aqueous solution by means of a syringe, perforated plate or tube or other appropriate extrusion means. Preferably, the aqueous solution may contain small amounts of buffering compounds, preservatives and  
25 the like. In the case of KL4 pulmonary surfactant, the solution of lipids and KL4 in ethanol is sterile filtered into sterile tris buffer at 45°C with vigorous mixing.

30 Once the ethanolic injection procedure is completed, the ethanolic solvent is removed in accordance with the invention through the use of a thin-film evaporator. Thin-film evaporators are well known devices designed for continuous feed concentration of

- 8 -

solutions. The device generally comprises an inner cylindrical evaporating chamber encircled by a thermal exchange jacket for providing proper temperature within the evaporating chamber. A rotatable shaft having rotor 5 blades secured thereto is positioned within the evaporating chamber. The rotor blades extend radially from the rotor shaft and are spaced in a manner sufficient to establish a film-forming relationship with the inner wall of the chamber. In operation, the dilute 10 solution is introduced into the evaporator chamber and a thin film of the solution is formed on the inner heat exchange surface of the chamber by the rotor blades. As the thin film is formed, heat or vacuum pressure applied to the chamber evaporates the solvent and concentrates 15 the solution. The evaporation can be performed on a continuous basis by continuous introduction and extraction of the solution from the chamber.

A variety of thin-film evaporators are known in the 20 art and are applicable for use in the present invention. For example, U.S patents 5,256,250 and 4,707,220 describe thin-film evaporators applicable for use in the process of the invention.

25 Thus, in accordance with the invention, a thin-film evaporator as described hereinbefore is used for the solvent removal following the ethanol injection process. Typically, in the case of KL4 pulmonary surfactant, the liposome suspension prepared by ethanol injection 30 contains an amount of ethanol in the range of 5-20% w/w that is subject to removal by the thin-film evaporation process. Preferably, the solution fed into the thin film evaporator should contain no more than 25% w/w ethanol. Once the lipid/ethanol solution has been

- 9 -

injected into the aqueous buffer, and the liposomal suspension is formed, the suspension is fed into the evaporation chamber of the thin-film evaporator through an inlet fitting designed for such purpose. The 5 liposome suspension is introduced into the apparatus while the rotor is operating. A peristaltic pump can be employed to regulate the loading of the suspension into the chamber. Once the suspension is drawn into the chamber, the rotors act to distribute the suspension as 10 a film on the interior of the heat-exchange walls, which are maintained within a temperature sufficient to keep the product at the appropriate transition temperature range. A vacuum is drawn on the chamber and the alcoholic solvent in the suspension is evaporated and 15 drawn from the chamber through an outlet. The concentrated suspension then exits the chamber at the opposite end. The whole process can be performed on a continuous basis with the suspension being fed and extracted from the thin-film evaporator as appropriate.

20

During the evaporation process, the temperature of the heat exchange surface is maintained by the recirculating heating fluid in the thermal exchange jacket so that the internal temperature of the material 25 in the evaporator is within the transition temperature range ( $T_c$ ) of the surfactant. This is the temperature at which the lipid surfactant is in a state of flux between "gel" and "liquid crystalline" phases. In the case of KL4 pulmonary surfactant composition, the thin film evaporation is conducted within the transition 30 temperature range of the DPPC:POPG:PA: KL4 surfactant (approximately 35-50°C), thereby enhancing the KL4 peptide insertion into the lipid bilayer and leading to a product with reduced viscosity and enhanced surface

- 10 -

5 tension lowering properties. During the liposome formation process, the ethanol solvent increases the fluidity of the lipid bilayer, thus allowing protein insertion into the lipid bilayer. By conducting thin-film evaporation within the transition temperature range of the surfactant composition, the peptide in the bulk phase inserts into the lipid bilayer more efficiently as the fluidity of the bilayer decreases due to solvent removal. Otherwise, KL4 peptide may remain in the bulk 10 aqueous phase outside the bilayer resulting in greater drug product viscosity and reduced surface tension lowering properties. If the process is conducted below the transition temperature range, drug product viscosity is increased due to KL4 peptide that is either excluded 15 from the bilayer (trapped outside during ethanol removal) or improperly incorporated into the bilayer. Surface tension lowering properties are compromised due to incomplete and incorrect KL4 bilayer insertion. Accordingly, the process of the present invention allows 20 for manufacture of KL4 pulmonary surfactant with enhanced surface tension lowering properties and lower viscosity, both of which lead to optimal *in vivo* performance.

25 For liposomal compositions intended for pharmaceutical uses, the process of the invention may be carried out under aseptic conditions. This is done by sterilizing the thin film evaporator, steaming-in-place or other techniques known in the art, and by feeding an 30 extracting the suspension under aseptic conditions. In addition, both the aqueous and ethanolic solutions can be sterile filtered before or during the injection process.

- 11 -

The examples presented below are provided as a further guide to the practitioner of ordinary skill in the art, and are not to be construed as limiting the invention in any way.

5

#### EXAMPLE 1

##### Preparation of KL4 Pulmonary Surfactant Liposome Composition

10

1L of 40mg/ml total phospholipid KL4 pulmonary surfactant is prepared by ethanol injection. 22.5g DPPC, 7.5g POPG, 4.5g palmitic acid and 0.8g KL4 peptide are dissolved in 250ml 95% ethanol and sterile filtered into 15 sterile tris buffer at 45°C.

20

Removal of residual ethanol is effected by thin-film evaporation using a rotary thin-film evaporator with an internal evaporative surface of 0.25 ft<sup>2</sup> and a film thickness of 1/32 inch. Two passes through the thin film evaporator are preferable to achieve an ethanol content below 0.1% w/w in the final product. The material prepared by ethanol injection as described above is first diluted with sterile-filtered Water For 25 Injection and then fed into the thin-film evaporator. As the material passes continuously through the thin film evaporator, ethanol and water are removed. The residence time for the material in the thin-film evaporator is approximately 1 minute. The conditions for each pass through the thin-film evaporator are as follows:

Feed rate: 45 mL/min  
Product Temperature: 40°C

- 12 -

Pressure: 30-80 mm Hg  
Feed temperature: 5-20°C  
Receiver temperature: 5-15°C  
Pass 1 dilution: 1.3L sterile-filtered Water for  
5 Injection  
Pass 2 dilution: 0.54L sterile-filtered Water  
for Injection

Once the material has passed through the thin-film  
10 evaporator, it is cooled to 5-15°C in the receiving  
vessel.

#### EXAMPLE 2

15 A 15L batch of 40mg/ml total phospholipid KL4 pulmonary surfactant is prepared in accordance with the procedure of Example 1 using 337.5g DPPC, 112.5g POPG, 67.5g palmitic acid and 12g KL4 peptide in 3.75L 95% ethanol.

20

#### EXAMPLE 3

#### Viscosity-Temperature Experiments

25 Three 300ml batches of KL4 pulmonary surfactant liposome composition were prepared by ethanol injection using thin film evaporation in accordance with the procedure of Example 1.

30 The product temperature at which the thin film evaporation was conducted was varied for the batches and the viscosity of the resulting product measured. Batches 1 and 3 were prepared below the transition temperature range at about 32°C while batch 2 was

- 13 -

prepared within the transition temperature range, at about 40°C. The viscosity of the material was then measured using a Brookfield DVII Viscometer. The results are set forth below in Table 1.

TABLE 1

## VISCOSEITY (cPs)

RPM	1min	2min	3min	4min	5min	6min	7min	8min	9min	10 min
BATCH 1										
0.3	5000	46670	44170	35000	30030	30830	30000	30000	30000	30000
1	13250	13250	13250	13250	13250	13000	13000	13000	13000	13000
10	4850	4300	3975	3775	3600	3475	3375	3300	3250	3175
BATCH 2										
0.3	4167	4167	4167	4167	4167	2500	2500	3333	2500	2500
1	1000	1000	1000	1000	1000	1000	1250	1250	1000	1000
10	1000	1000	925.0	875.0	850.0	825.0	800.0	775.0	750.0	750.0
BATCH 3										
0.3	35830	32500	31670	29170	29170	27500	26670	26670	26620	24670
1	11000	10750	11250	11250	11250	11250	11250	11250	11250	11000
10	4825	4150	3800	3600	3500	3450	3375	3350	3325	3250

- 15 -

The conditions for each pass through the thin film evaporator for the three batches were as follows:

5      Batch 1 (Control)

Feed rate:            - 20 ml/min  
Product temp.:       - 32°C  
Pressure:            - 26 mm Hg

10

Batch 2

Feed rate:            - 30 ml/min  
Product temp.:       - 40°C  
15      Pressure:       - 38-40 mm Hg

Batch 3

Feed rate:            - 20 ml/min  
20      Product Temp.:       - 32°C  
Pressure:            - 26 mm Hg

25      The foregoing results demonstrate the Batch 2, prepared within the transition temperature range of the surfactant composition, exhibited greatly reduced viscosity compared to batches 1 and 3 prepared at a lower product temperature.

- 16 -

CLAIMS

1. In a process for preparing liposomal suspensions of proteins or other poorly soluble compounds by ethanolic injection, wherein a solution of the protein or other poorly soluble compound and an encapsulating amount of a suitable lipid in an alcoholic solvent is prepared and injected into an aqueous solution of appropriate ionic strength; the improvement which comprises removing the alcoholic solvent by thin-film evaporation within the transition temperature range of the liposomal suspension.
2. The process of claim 1 wherein the alcoholic solvent is ethanol.
3. The process of claim 1 wherein the protein is KL4 peptide.
4. The process of claim 1 wherein the suitable lipid is selected from the group consisting of dipalmitoyl-phosphatidylcholine (DPPC), palmitoyloleoylphosphatidylglycerol (POPG), palmitic acid (PA), egg phosphatidylcholine (EPC), egg phosphatidylglycerol (EPG), cholesterol, dimyristoylphosphatidylglycerol (DMPG) and dimyristoylphosphatidylcholine (DMPC).
5. The process of claim 1 wherein the liposomal suspension is KL4 pulmonary surfactant.
6. The process of claim 5 wherein the transition temperature range is approximately 35-50°C.

- 17 -

7. The process of claim 1 wherein the alcoholic solvent is a lower alkanol of one to six carbon atoms.

5 8. The process of claim 1 wherein the alcoholic solvent contains a solubilizing amount of a fluorinated alcohol.

9. The process of claim 1 wherein the alcoholic solvent contains a solubilizing amount of a aprotic solvent.

THIS PAGE IS BLANK

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 9/127</b>		A3	(11) International Publication Number: <b>WO 97/35559</b> (43) International Publication Date: <b>2 October 1997 (02.10.97)</b>
(21) International Application Number: <b>PCT/US97/03380</b> (22) International Filing Date: <b>4 March 1997 (04.03.97)</b>  (30) Priority Data: <b>60/014,227</b> <b>27 March 1996 (27.03.96)</b> <b>US</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(71) Applicant: <b>ORTHO PHARMACEUTICAL CORPORATION [US/US]; US Route #202, Raritan, NJ 08869-0602 (US)</b>  (72) Inventors: <b>KLIMCHAK, Robert, J.; 121 Rockafellow Mill Road, Flemington, NJ 08822 (US). GLAVINOS, Peter, G., Jr.; 890 Pebble Hill Road, Doylestown, PA 18901 (US).</b>  (74) Agents: <b>CIAMPORCERO, Audley et al.; Johnson &amp; Johnson, One Johnson &amp; Johnson Plaza, New Brunswick, NJ 08933-7003 (US).</b>		<b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  (88) Date of publication of the international search report: <b>20 November 1997 (20.11.97)</b>	
<b>(54) Title:</b> MANUFACTURE OF LIPOSOMES AND LIPID-PROTEIN COMPLEXES BY ETHANOLIC INJECTION AND THIN FILM EVAPORATION			
<b>(57) Abstract</b>  A method for preparing liposomal suspensions which comprises preparing a solution of a poorly soluble protein or other poorly soluble compound and an encapsulating amount of a suitable lipid in an alcoholic solvent, injecting the resulting solution into an aqueous solution of appropriate ionic strength, and removing the alcoholic solvent by thin-film evaporation at the transition temperature of the liposomal suspension. This process is suitable for continuous production on an industrial manufacturing scale. It is of particular application in the preparation of KL4 pulmonary surfactant composition, wherein the thin film evaporation is conducted within the transition temperature range of the surfactant (approximately 35-50 °C), thereby enhancing the KL4 peptide insertion into the lipid bilayer and leading to a product with reduced viscosity and enhanced surface tension lowering properties.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/03380

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 6 A61K9/127

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 91 16039 A (SCHERING AKTIENGESELLSCHAFT) 31 October 1991 see page 1, paragraph 1 see page 4, paragraph 4 see page 5, line 1 - line 19 see page 6, paragraph 6 ---	1,2,4,6, 7,9
Y	US 4 405 652 A (BOUCHER) 20 September 1983 see claims 1-16 ---	1,2,4,6, 7,9
A	DE 40 38 075 C (B. BRAUN MELSUNGEN AG) 19 March 1992 see page 3, line 24 - line 41 ---	1,6 -/--

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

1

Date of the actual completion of the international search

7 October 1997

Date of mailing of the international search report

15.10.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

## INTERNATIONAL SEARCH REPORT

Internal Application No	PCT/US 97/03380
-------------------------	-----------------

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 260 273 A (COCHRANE ET AL.) 9 November 1993 cited in the application see column 14; table 3 see column 15, line 21 - column 16, line 2 ---	3,5
A	US 4 935 171 A (BRACKEN) 19 June 1990 cited in the application see the whole document ---	1-9
T	WO 97 19108 A (ORTHO PHARMACEUTICAL CORPORATION) 29 May 1997 see the whole document -----	1-9

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Internal	Application No
PCT/US 97/03380	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9116039 A	31-10-91	DE 4013580 A AT 141503 T AU 651969 B AU 7593391 A CA 2041075 A DE 59108097 D EP 0478727 A ES 2093701 T JP 4506814 T		31-10-91 15-09-96 11-08-94 07-11-91 25-10-91 26-09-96 08-04-92 01-01-97 26-11-92
US 4405652 A	20-09-83	AU 555176 B AU 8533782 A BE 893991 A BR 8300175 A CA 1183483 A DE 3241187 A FR 2520005 A GB 2113712 A,B GB 2141735 A,B JP 1747227 C JP 4036673 B JP 58129969 A LU 84332 A NL 8203029 A SE 459098 B SE 8204210 A US 4570534 A US 4643083 A		18-09-86 28-07-83 16-11-82 11-10-83 05-03-85 28-07-83 22-07-83 10-08-83 03-01-85 25-03-93 16-06-92 03-08-83 28-02-83 16-08-83 05-06-89 07-07-82 18-02-86 17-02-87
DE 4038075 C	19-03-92	AT 117544 T DE 59104404 D EP 0488142 A ES 2068473 T		15-02-95 09-03-95 03-06-92 16-04-95
US 5260273 A	09-11-93	US 5164369 A AU 666857 B AU 2177792 A CA 2111342 A EP 0590006 A JP 6508619 T		17-11-92 29-02-96 12-01-93 23-12-92 06-04-94 29-09-94

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal ref.	Application No
	PCT/US 97/03380

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5260273 A		US 5407914 A WO 9222315 A AU 3960089 A DK 439089 A EP 0350506 A EP 0593094 A JP 2502917 T NO 177309 B WO 8906657 A	18-04-95 23-12-92 11-08-89 05-09-89 17-01-90 20-04-94 13-09-90 15-05-95 27-07-89
US 4935171 A	19-06-90	AT 127014 T AU 5103990 A DE 69022034 D DE 69022034 T EP 0457833 A ES 2075894 T JP 4504527 T WO 9008535 A US 5028297 A	15-09-95 24-08-90 05-10-95 11-04-96 27-11-91 16-10-95 13-08-92 09-08-90 02-07-91
WO 9719108 A	29-05-97	AU 7459596 A	11-06-97